GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTENQ) » Definitions » ROC %

YTENQ (Yield10 Bioscience) ROC % : -216.35% (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Yield10 Bioscience's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -216.35%.

As of today (2024-12-15), Yield10 Bioscience's WACC % is 1.18%. Yield10 Bioscience's ROC % is -254.69% (calculated using TTM income statement data). Yield10 Bioscience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Yield10 Bioscience ROC % Historical Data

The historical data trend for Yield10 Bioscience's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience ROC % Chart

Yield10 Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -121.04 -163.75 -228.38 -316.81 -358.10

Yield10 Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -384.94 -344.95 -286.36 -190.96 -216.35

Yield10 Bioscience ROC % Calculation

Yield10 Bioscience's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-14.417 * ( 1 - 0% )/( (3.762 + 4.29)/ 2 )
=-14.417/4.026
=-358.10 %

where

Yield10 Bioscience's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-12.812 * ( 1 - 0% )/( (5.932 + 5.912)/ 2 )
=-12.812/5.922
=-216.35 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yield10 Bioscience  (OTCPK:YTENQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Yield10 Bioscience's WACC % is 1.18%. Yield10 Bioscience's ROC % is -254.69% (calculated using TTM income statement data). Yield10 Bioscience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Yield10 Bioscience ROC % Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience Business Description

Traded in Other Exchanges
N/A
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038